Novartis touts new T-cell therapy data in race for FDA approval – Reuters
Reuters |
Novartis touts new T–cell therapy data in race for FDA approval
Reuters Globally, there are some 183 CAR–T trials underway. In March, Novartis filed CTL019 with the U.S. Food and Drug Administration for fast-track approval in B-cell acute lymphoblastic leukemia (ALL) in young patients. The FDA has scheduled a July 12 … As Novartis preps for first CAR–T FDA AdComm, Juliet data revealed Novartis posts landmark CAR–T data as head-to-head rivalry with Kite Pharma looms Novartis' CAR–T stacks up to Kite in lymphoma |
